^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RNASEK (Ribonuclease K)

    i
    Other names: RNASEK, Ribonuclease K, Ribonuclease, RNase K, Ribonuclease Kappa, RNase Kappa, MGC71993, RNase K
    Associations

    News

    Trials
    8ms
    Pan-Cancer Analysis Reveals Ribonuclease K (RNASEK) as a Potential Prognostic Biomarker in Pancreatic Cancer and a Diagnostic Indicator Across Multiple Human Cancers. (PubMed, Cureus)
     In conclusion, this study's pan-cancer analysis revealed that RNASEK could be a potential diagnostic biomarker in six cancer types, including BLCA, CHOL, ESCA, HNSC, LIHC, and THCA, and as a prognostic biomarker in PAAD.
    Journal • Pan tumor
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • RNASEK (Ribonuclease K)
    over3years
    Role of the Ribonuclease ONCONASE in miRNA Biogenesis and tRNA Processing: Focus on Cancer and Viral Infections. (PubMed, Int J Mol Sci)
    In cells infected by viruses, ONC hampers viral spread by digesting the primer tRNAs necessary for viral DNA replication. In this scenario, new therapeutic tools might be developed by exploiting the action of ONC-elicited RNA derivatives.
    Review • Journal
    |
    RNASEK (Ribonuclease K)
    |
    Onconase (ranpirnase)
    over3years
    Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer. (PubMed, BMC Cancer)
    JQ1-GSK2801 synergistically inhibits proliferation and results in selective gene regulation. Besides suggesting that combinatorial use could be useful therapeutics for the treatment of TNBC, the findings provide a glimpse into potential mechanisms of action for this combination therapy approach.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL17A (Interleukin 17A) • MUC19 (Mucin 19, Oligomeric) • TAGLN (Transgelin) • RNASEK (Ribonuclease K)
    |
    JQ-1
    4years
    RSPO2/RANKL-LGR4 signaling regulates osteoclastic pre-metastatic niche formation and bone metastasis. (PubMed, J Clin Invest)
    Furthermore, soluble LGR4 extracellular domain (ECD) protein, acting as a decoy receptor for RSPO2 and RANKL, significantly alleviated bone metastasis and osteolytic lesions in mouse bone metastasis model. These findings provide unique insights into the functional role of OPs as key components of pre-metastatic niche for BCa bone metastasis, indicate RSPO2/RANKL-LGR4 signaling as a promising target for inhibiting BCa bone metastasis.
    Journal
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1) • RSPO2 (R-Spondin 2) • LGR4 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 4) • RNASEK (Ribonuclease K) • RSPO1 (R-Spondin 1)